Retinal Vein Occlusion Pipeline Featuring 15+ Companies Expected to Change the Pace of the Retinal Vein Occlusion Treatment

"A PPV may also ablate neovascularization that can cause neovascular glaucoma in the anterior segment. Laser pan-retinal photocoagulation (PRP) can be done to treat neovascularization, with the goal of devitalizing some of the retinal tissue to prevent further neovascularization and treat iris neovascularization. There is no evidence at this time supporting prophylactic PRP without neovascularization"

The drug is described in detail in the Retinal Vein Occlusion pipeline report, along with its mechanism of action, Retinal Vein Occlusion clinical trials, Retinal Vein Occlusion NDA approvals (if any), and product development activities that include technology, Retinal Vein Occlusion collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related information.

DelveInsight's, "Retinal Vein Occlusion Pipeline Insight, 2023," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including Retinal Vein Occlusion clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Retinal Vein Occlusion Pipeline Report

• DelveInsight's Retinal Vein Occlusion Pipeline analysis depicts the space with 15+ active players working to develop 15+ pipeline therapies.

• The leading Retinal Vein Occlusion Companies include Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.

• Promising Retinal Vein Occlusion Pipeline Therapies include Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.

• The Retinal Vein Occlusion Companies and academics that are working to assess challenges and seek opportunities that could influence Retinal Vein Occlusion R&D. The Retinal Vein Occlusion pipeline therapies under development are focused on novel approaches to treat/improve the Retinal Vein Occlusion disease condition.

Request a sample and discover the recent breakthroughs happening in the Retinal Vein Occlusion Pipeline landscape @ Retinal Vein Occlusion Pipeline Outlook Report- https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Retinal Vein Occlusion Overview
Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused). Non-ischemic CRVO is the most common, accounting for about 70% of cases. A primary risk factor for the development of central retinal vein occlusion is age, with 90% of patients older than 50 years old.

Recent Developmental Activities in the Retinal Vein Occlusion Treatment Landscape

• The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema.

For further information, refer to the detailed Retinal Vein Occlusion Drugs Launch, Retinal Vein Occlusion Developmental Activities, and Retinal Vein Occlusion News, click here for Retinal Vein Occlusion Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Retinal Vein Occlusion Emerging Drugs Profile

• KSI-301: Kodiak sciences
The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.

• 601: Sunshine Guojian Pharmaceutical
601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.

• IBE-814: Ripple Therapeutics
IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).

Retinal Vein Occlusion Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Retinal Vein Occlusion. The companies which have their Retinal Vein Occlusion drug candidates in the mid to advanced stage, i.e. Phase III include, Kodiak sciences

Find out more about the Retinal Vein Occlusion Pipeline Segmentation, Therapeutics Assessment, Retinal Vein Occlusion Emerging Drugs @ Retinal Vein Occlusion Treatment Landscape- https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Retinal Vein Occlusion Pipeline Report

• Coverage- Global

• Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.

• Retinal Vein Occlusion Pipeline Therapies- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.

• Retinal Vein Occlusion Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Table of Content

1. Introduction
2. Executive Summary
3. Retinal Vein Occlusion: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. KSI-301: Kodiak sciences
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. 601: Sunshine Guojian Pharmaceutical
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. MHU650: Novartis
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Retinal Vein Occlusion Key Companies
17. Retinal Vein Occlusion Key Products
18. Retinal Vein Occlusion- Unmet Needs
19. Retinal Vein Occlusion- Market Drivers and Barriers
20. Retinal Vein Occlusion- Future Perspectives and Conclusion
21. Retinal Vein Occlusion Analyst Views
22. Retinal Vein Occlusion Key Companies
23. Appendix

Got Queries? Find out the related information on Retinal Vein Occlusion Mergers and acquisitions, Retinal Vein Occlusion Licensing Activities @ Retinal Vein Occlusion Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.